Register for this webinar to learn about setting and managing indices for common interferents to ensure quality results. With your registration, you will have access to the recording on demand through November 30, 2023.
Pre-analytical errors are the most frequent source of laboratory errors and can negatively impact patient care. Evaluation of specimen suitability for downstream analytical testing and identification of potential interferents in the clinical laboratory is critical for the generation of actionable clinical results. Hemolysis (H), icterus (I) and lipemia (L) are common interferents that can compromise the integrity of clinical samples in downstream analyses. In this webinar, Dr. Marzinke will discuss strategies to empirically verify or derive HIL limits for routinely tested analytes, evaluation of quality control material to monitor HIL analytical performance, and approaches to implement a quality assurance program to monitor HIL analytical performance.
This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, point-of-care coordinators, pathologists, toxicologists, fellows, residents, in-training individuals, and other laboratory professionals overseeing/conducting within this topic.
At the end of this activity, participants will be able to:
- Implement workflows to verify analytical thresholds for hemolysis, icterus, and lipemia.
- Develop strategies to evaluate specimen interferent quality control material
- Discuss approaches to implement a quality assurance program for monitoring performance of hemolysis, icterus, and lipemia indices
Mark Marzinke, PhD, DABCC, FADLM
Professor of Pathology and Medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine
DISCLOSURES AND STATEMENT OF INDEPENDENCE
The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
- Mark Marzinke, PhD, DABCC, FADLM
Grant/Research Support: NIH, ViiV, Gilead Sciences, Merck
Consultant Fee: Bio-Rad
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID# 4129. This activity was planned in accordance with ACCENT® Standards and Policies.
SUCCESSFUL COMPLETION STATEMENT
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].